Currently, CD19-directed CAR T-cell therapy is being explored particularly in the clinical management of B-cell malignancies including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) [2]. Here, CD19 is linked to non-Hodgkin lymphoma.